New Edition of the Hayes' Principles and Methods of Toxicology Provides Critical New Chapter on Food Safety and Foodborne Toxicants

IRVINE, Calif., Oct. 6, 2014 /PRNewswire/ -- ChromaDex Corp.  (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, cosmetic and pharmaceutical industries, has announced that two leaders of its Spherix Consulting affiliate, A. Wallace Hayes, Ph.D., senior science advisor, and Claire Kruger, Ph.D., president, served as editors for the sixth edition of the influential textbook, Hayes' Principles and Methods of Toxicology.  

"This volume is a benchmark resource in the field," said Kruger, who co-authored the new food safety chapter with Hayes, as well as serving with Hayes as editor of the massive, 2,184-page volume. "Spherix Consulting's role in revising and updating the new edition of this volume – as well as authoring the exciting new food toxicology chapter – is a testimony to the company's expertise in the field of toxicology. We are honored to have played a part in creating a book that will be widely used by students and professionals around the world."

Hayes' Principles and Methods of Toxicology has long been one of the foremost references for the concepts, methodologies, and assessments integral to toxicology. New chapters in the sixth edition, which was published Sept. 5, deal with the importance of dose response, systems toxicology, food safety, the humane use and care of animals and neurotoxicology. 

The new food safety chapter, "Food Safety and Foodborne Toxicants," was co-authored by Kruger, Hayes and Dietrich Conze, Ph.D., Spherix's senior science director, along with Chada Reddy, Ph.D., an associate professor at the University of Missouri Department of Biomedical Sciences. The chapter covers standards of safety and regulatory paths for food additives, GRAS substances and dietary supplements, with special emphasis on important issues in the field such as food allergy, foodborne toxicants, and naturally occurring toxins in the food supply.

Kruger has more than 25 years of consulting experience, with her primary area of expertise being in foods, consumer products and pharmaceuticals, where she provides scientific, regulatory and strategic support to clients in the U.S. and international regulatory arenas. Her clients include food, drug and dietary supplement manufacturers, agricultural producers, biotechnology companies, trade associations and law firms. Kruger is also an instructor at Harvard University. Hayes is a toxicologist with more than 35 years of experience in industry and academics. In his role as senior science advisor at Spherix, he provides strategic, scientific and regulatory guidance. He also holds appointments at the Harvard School of Public Health as a visiting scientist and with the School of Public Health, University of Massachusetts, Amherst. He is currently a member of the Food Advisory Committee, U.S. Food and Drug Administration.

Spherix Consulting will have a significant presence at the upcoming SupplySide West conference in Las Vegas, Nev., Oct. 7-9.  Spherix will be exhibiting at Booth 20087 along with the ChromaDex's other business groups: Ingredients, cGMP Consulting, Analytical Services and Reference Standards. In addition, Kruger will be presenting on the scientific standards of the GRAS process as part of the SupplySide Rockstars educational series on Oct. 9 at 11:45 a.m. The RockStars event features experts with unique perspectives on key industry issues delivering their insights in a quick-paced format similar to the TED talks.

About ChromaDex:
ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure^® pterostilbene; ProC3G^®, a natural black rice containing cyanidin-3-glucoside; PURENERGY^®, a caffeine-pTeroPure® cocrystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a potent NAD+ booster and novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.

About Spherix Consulting:
Spherix Consulting's global team of experienced advisors provides clients in the food, dietary supplement, consumer product, and pharmaceutical industries with scientific solutions that result in regulatory success.  Our experts evaluate and manage risks associated with new and legacy products under regulatory scrutiny, subject to product liability and tort litigation, and/or exposed to changing scientific standards or public perceptions.  We provide the expertise in scientific assessment, regulatory submission, and product stewardship necessary to navigate the ever-changing world-wide regulatory climate.  Our customized strategies help minimize cost, reduce risk, and ensure success by assuring the safety, regulatory compliance, and benefit of our clients' unique products and projects.

Our services include Generally Recognized As Safe (GRAS) self-determinations and notifications, New Dietary Ingredient Notifications (NDINs), pharmaceutical regulatory submissions (Investigational New Drugs (IND), New Drug Applications (NDA), Abbreviated New Drug Applications (ANDA), 505(b)(2) Applications), health and structure/function claims support, food additive and USDA petitions, food contact substance notifications, animal feed ingredient GRAS determinations, AAFCO submissions, litigation support, preclinical and clinical study design and oversight, manuscript preparation and submission, novel food submissions and substantial equivalence notifications, cGMP compliance, and drug development due diligence.

Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in ChromaDex's business. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, ChromaDex's Quarter Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Media Inquiries: 
Beckerman PR
Jerry Schranz 
201-465-8020 
[email protected]  

ChromaDex Company Contact:
Laura Kelly, Executive Assistant
949-419-0288
[email protected]

Statements in this press release have not been evaluated by the Food and Drug Administration.  Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

SOURCE ChromaDex Corp.